S'abonner

Effect of mass drug administration on malaria incidence in southeast Senegal during 2020–22: a two-arm, open-label, cluster-randomised controlled trial - 10/01/25

Doi : 10.1016/S1473-3099(24)00741-2 
El-hadji Konko Ciré Ba, PhD a, *, Michelle E Roh, PhD b, c, *, Abdoulaye Diallo, MD a, Tidiane Gadiaga, MD d, Amadou Seck, MSc a, Sylla Thiam, MD a, Ari Fogelson, MSc e, Seynabou Gaye, MD g, Ibrahima Diallo, PharmD g, Aminata Colle Lo, PhD a, Elhadji Diouf, MPH a, b, Oumar Gallo Ba, BSc a, Alioune Badara Gueye, MD h, Xue Wu, MMed b, c, Paul Milligan, ProfPhD e, Tabitha Kibuka, MPH b, Moustapha Hama, MHA b, Erin Eckert, PhD b, Julie Thwing, MD i, Adam Bennett, PhD b, j, Roly Gosling, ProfMD b, c, f, Jimee Hwang, MD i, k, Doudou Sene, MD g, Fatou Ba, PhD g, Bayal Cissé, MD d, Katharine Sturm-Ramirez, PhD h, Michelle S Hsiang, MD b, c, * , Jean Louis Ndiaye, ProfMD a, *
a Department of Parasitology, Research and Training for Health Science, Université Iba Der Thiam de Thiès, Thiès, Senegal 
b Impact Malaria, US President’s Malaria Initiative, Washington, DC, USA 
c Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA 
d District of Tambacounda, Ministry of Health and Social Action, Tambacounda, Senegal 
e Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK 
f Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK 
g Senegal National Malaria Control Programme, Ministry of Health and Social Action, Dakar, Senegal 
h US President’s Malaria Initiative, US Agency for International Development, Dakar, Senegal 
i Malaria Branch, US President’s Malaria Initiative, US Centers for Disease Control and Prevention, Atlanta, GA, USA 
j PATH, Seattle, WA, USA 
k US Public Health Service, Rockville, MD, USA 

* Correspondence to: Michelle E Roh, Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA 94158, USA Institute for Global Health Sciences University of California, San Francisco San Francisco CA 94158 USA
Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 10 January 2025

Summary

Background

In Africa, the scale-up of malaria-control interventions has reduced malaria burden, but progress towards elimination has stalled. Mass drug administration (MDA) is promising as a transmission-reducing strategy, but evidence from low-to-moderate transmission settings is needed. We aimed to assess the safety, coverage, and effect of three cycles of MDA with dihydroartemisinin–piperaquine plus single, low-dose primaquine on Plasmodium falciparum incidence and prevalence in southeast Senegal.

Methods

We conducted a two-arm, open-label, cluster-randomised controlled trial in villages in the Tambacounda health district of southeast Senegal. Eligible villages had a population size of 200–800, were within a health-post catchment area with an annual malaria incidence of 60–160 cases per 1000 people, and had an established or planned Prise en Charge à Domicile Plus model. We randomly assigned villages (1:1) using a stratified, constrained randomisation approach to receive either three cycles of MDA with oral dihydroartemisinin–piperaquine plus single, low-dose primaquine administered at 6-week intervals (intervention) or to standard of care, which included three cycles of seasonal malaria chemoprevention (SMC) with oral sulfadoxine–pyrimethamine plus amodiaquine administered at 4-week intervals (control). Participants, the field team, and all investigators, including those who assessed outcomes and analysed data, were unmasked to allocation assignment. Laboratory technicians were masked to intervention assignment. The primary outcome was village-level, P falciparum-confirmed malaria incidence in the post-intervention year (ie, July to December, 2022). Secondary outcomes included malaria incidence during the intervention year (ie, July to December, 2021), coverage and safety of MDA, and adverse events. We conducted analyses using an intention-to-treat approach. The trial is registered with ClinicalTrials.gov (NCT04864444) and is completed.

Findings

Between Sept 1 and Oct 25, 2020, 523 villages were geolocated and screened for eligibility; 111 met the inclusion criteria. Of these, 60 villages were randomly selected and assigned to the intervention arm or control arm. Distribution coverage of all three doses of dihydroartemisinin–piperaquine was 6057 (73·6%) of 8229 participants in the first cycle, 6836 (78·8%) of 8673 participants in the second cycle, and 7065 (81·3%) of 8690 participants in the third cycle. Distribution coverage of single, low-dose primaquine was 6286 (78·6%) of 7999 participants in the first cycle, 6949 (82·1%) of 8462 participants in the second cycle, and 7199 (84·0%) of 8575 participants in the third cycle. Distribution coverage of all three doses of SMC was 3187 (92·2%) of 3457 children aged 3–120 months in the first cycle, 3158 (91·8%) of 3442 children aged 3–120 months in the second cycle, and 3139 (91·4%) of 3434 children aged 3–120 months in the third cycle. In the intervention year (ie, July to December, 2021), the adjusted effect of MDA was 55% (95% CI 28 to 71). In the post-intervention year (ie, July to December 2022), the adjusted MDA effect was 26% (–17 to 53). Malaria incidence during the transmission season of the post-intervention year was 126 cases per 1000 population in the intervention arm and 146 cases per 1000 population in the control arm. No serious adverse events were reported.

Interpretation

In southeast Senegal, a low-to-moderate transmission setting where malaria-control measures have been scaled up, three cycles of MDA with dihydroartemisinin–piperaquine plus single, low-dose primaquine was safe and reduced malaria burden during the intervention year. However, its sustained effect was weak and continuation of MDA or another transmission-reducing strategy could be required.

Funding

US President’s Malaria Initiative.

Le texte complet de cet article est disponible en PDF.

Plan


© 2025  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.